MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in
epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a …

Recent advances in the understanding of immune function and the interactions with tumour
cells have led to the development of various cancer immunotherapies and strategies for …

OBJECTIVES.: To determine the CA125 tissue expression levels in borderline and invasive
epithelial ovarian tumor tissues. Secondly, to evaluate whether CA125 tissue expression …

New high-throughput screening technologies such as complementary (cDNA) microarrays
allow identification of hundreds of candidate genes in one experiment. To prioritize the leads …

Ovarian cancer is an aggressive gynaecological cancer with extremely poor prognosis, due
to late diagnosis as well as the development of chemoresistance after first-line therapy …

Many members of the human kallikrein gene family were found to be differentially expressed
in various malignancies and some are useful cancer diagnostic/prognostic markers. KLK9 is …

Prognostic markers may potentially help to individualize treatment within subgroups of
patients. In a recent study the level of cancer antigen 125 expression was consistently found …

Purpose: KLK15 is a newly cloned human kallikrein gene. Many kallikreins were found to be
differentially expressed in ovarian cancer. Like other kallikreins, KLK15 is regulated by …

Background Serum levels of CA125 measured before any treatment have been evaluated in
epithelial ovarian cancer (EOC) as a predictor of patient survival; however, results in survival …

To study KLK14 gene expression in endocrine-related cancers, we studied its hormonal
regulation in breast and ovarian cancer cell lines. Our kinetic and blocking experiments …